User login
Key clinical point: Polymorphisms of CYP2A6 and ABCC4 genes were associated with a protective effect against the development of chronic myeloid leukemia (CML). These findings highlight the underlying genetic predisposition of individuals to develop CML.
Major finding: Individuals with the C allele of the rs28399433 polymorphism of CYP2A6 gene (odds ratio [OR], 0.33; 95% confidence interval [CI], 0.14-0.78; P = .008) and the CC genotype of the rs3742106 polymorphism of ABCC4 gene (OR, 0.30; 95% CI, 0.10-0.88; P = .020) had a significantly reduced susceptibility to CML vs. other genotypes.
Study details: This retrospective study assessed an admixed population of 269 individuals including 143 patients with CML and 126 healthy controls from the Amazon region of Brazil.
Disclosures: No specific funding source was identified. The authors declared no conflicts of interest.
Source: Monte N et al. Mol Genet Genomic Med. 2021 May 29. doi: 10.1002/mgg3.1694.
Key clinical point: Polymorphisms of CYP2A6 and ABCC4 genes were associated with a protective effect against the development of chronic myeloid leukemia (CML). These findings highlight the underlying genetic predisposition of individuals to develop CML.
Major finding: Individuals with the C allele of the rs28399433 polymorphism of CYP2A6 gene (odds ratio [OR], 0.33; 95% confidence interval [CI], 0.14-0.78; P = .008) and the CC genotype of the rs3742106 polymorphism of ABCC4 gene (OR, 0.30; 95% CI, 0.10-0.88; P = .020) had a significantly reduced susceptibility to CML vs. other genotypes.
Study details: This retrospective study assessed an admixed population of 269 individuals including 143 patients with CML and 126 healthy controls from the Amazon region of Brazil.
Disclosures: No specific funding source was identified. The authors declared no conflicts of interest.
Source: Monte N et al. Mol Genet Genomic Med. 2021 May 29. doi: 10.1002/mgg3.1694.
Key clinical point: Polymorphisms of CYP2A6 and ABCC4 genes were associated with a protective effect against the development of chronic myeloid leukemia (CML). These findings highlight the underlying genetic predisposition of individuals to develop CML.
Major finding: Individuals with the C allele of the rs28399433 polymorphism of CYP2A6 gene (odds ratio [OR], 0.33; 95% confidence interval [CI], 0.14-0.78; P = .008) and the CC genotype of the rs3742106 polymorphism of ABCC4 gene (OR, 0.30; 95% CI, 0.10-0.88; P = .020) had a significantly reduced susceptibility to CML vs. other genotypes.
Study details: This retrospective study assessed an admixed population of 269 individuals including 143 patients with CML and 126 healthy controls from the Amazon region of Brazil.
Disclosures: No specific funding source was identified. The authors declared no conflicts of interest.
Source: Monte N et al. Mol Genet Genomic Med. 2021 May 29. doi: 10.1002/mgg3.1694.